Compare Gilead Sciences, Inc. (GILD) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Prudential Financial Inc — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Prudential Financial Inc trades at $111.8 (market cap $39.17B). The key difference: Gilead Sciences, Inc. is far larger — about 4.7× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.93%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Prudential Financial Inc for 145 Days on average.
| GILD | PRU | |
|---|---|---|
Market Cap | $182.40B | $39.17B |
Volume | 4,469,821 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $155.80 | $125.13 |
52-Week Low | $116.74 | $92.00 |
Typical Hold Time | 111 Days | 145 Days |
Enterprise Value | $205.46B | $67.95B |
Dividend Yield | 2.23% | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Prudential Financial (PRU) trades at $112.36, down 1.04% with a bearish technical outlook. The stock shows attractive valuation metrics including a P/E of 10.19 and P/S of 0.61, while recent earnings beat expectations in two of the last three quarters. The company is executing a strategic overhaul including a $3 billion capital rotation plan and emerging market exits, while benefiting from higher interest rates that boost investment income.
PRU presents a value opportunity with strong fundamentals but faces near-term technical pressure. The 67.57% analyst hold rating reflects cautious optimism, with the current price above the $105.67 consensus target. Key risks include execution of strategic initiatives and annuity market competition, while higher rates provide tailwinds for insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
